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Abstract
Sepsis and septic shock remain a considerable therapeutic challenge. Despite signiﬁcant advances in supportive care and the availability
of potent, broad-spectrum antibiotics, the overall mortality due to sepsis is still approximately 35%, and this increases to 60% if patients
develop septic shock. Antibiotics constitute a necessary part of the treatment of sepsis, and there is probably considerable scope to
improve the way in which they are used. Nevertheless, antibiotics alone, even used optimally, are probably not sufﬁcient to substantially
reduce the mortality that accompanies the multiorgan failure that occurs in septic patients. For this reason, considerable efforts have
been expended in developing non-antibiotic (or so-called adjunctive) forms of treatment, and here the general approaches to these
types of treatment are reviewed. There are three main categories: improvements in supportive care, treatments aimed at bacterial viru-
lence factors, and treatments aimed at host mediators. This is not intended to be a comprehensive review, but rather to provide exam-
ples in each category to illustrate the general principles—and the hurdles—that have characterized these approaches to therapy.
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Introduction
Large epidemiological studies and clinical trials in patients with
sepsis have shown that the overall mortality rate is approxi-
mately 35% and that, in patients with more advanced disease,
septic shock, the mortality rate increases to 60% or more. It is
worth emphasizing that these alarming ﬁgures represent the
outcome of ‘standard of care’ treatment: in other words, at
least one-third of patients with this condition die, despite
treatment on an intensive-care unit (ICU), receiving full sup-
portive care and appropriate antibiotics. Sepsis is not rare
[1,2]; it is one of the commonest causes of death on most
ICUs. Why is it that this condition remains so challenging,
despite all our efforts to improve the outcome? More particu-
larly, why is it that antibiotics have not provided the answer?
After all, sepsis is ‘simply’ the systemic response to infection,
generally due to common bacterial organisms such as Staphylo-
coccus aureus, streptococci, Enterobacteriaceae and Pseudomo-
nas aeruginosa. Although we rarely know the exact
microbiological diagnosis when the patient ﬁrst presents, we
now have at our disposal a wide array of broad-spectrum anti-
biotics that can—and should—be deployed empirically. Why
is it that this has seemingly not been sufﬁcient to make a signif-
icant impact on the progress of the disease?
There are, perhaps, two answers to this question. We
should ﬁrst acknowledge that antibiotics are indeed highly
effective, but that we need to use them appropriately. Sepsis
is most effectively managed when it is recognized early and
treatment is started quickly. This is well illustrated by a
recent study that demonstrated a clear relationship between
the delay in starting antibiotics and the eventual outcome
[3]. When antibiotics were started within 1 h of documented
hypotension, survival was 79.9%. Each subsequent hour of
delay over the next 6 h was associated with an average
decrease in survival of 7.6%. Furthermore, the antibiotics
chosen need to be appropriate. Several clinical trials demon-
strated that there was a signiﬁcant difference in the outcome
when the regimen used empirically was subsequently shown
to be active against the causative organism [4,5]. This is a
matter not just of spectrum of activity, but also of pharma-
codynamics, an aspect of the antibiotic treatment of septic
patients that has perhaps been under-appreciated [6–8].
But the second explanation for the failure of conventional
therapy is that the pathophysiology of sepsis is the result of
a highly complex set of processes in which the host response
becomes dysregulated and causes cellular damage, tissue
damage, and, ultimately, organ damage. Although antibiotics
are necessary elements in the treatment of sepsis by the
time that the clinical picture has been recognized they are
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unlikely to be sufﬁcient alone, and it is for this reason that
so much attention has been paid to adjunctive therapies that
might address the underlying pathological processes. This is
the focus of this special theme section of the journal.
It is not the purpose of this overview to present a com-
plete and detailed review of every aspect of the subject, but
rather to provide a framework in which to consider the
other articles in this section. There are three broad
approaches to adjunctive (non-antibiotic) therapy that need
to be considered (Table 1).
Improving Supportive Care
In developed countries, most septic patients are cared for in
the ICU, and the treatment of septic patients represents a
collaboration between intensive-care and infection specialists.
There have been substantial developments in the haemody-
namic management of sepsis, which, although not of speciﬁc
interest to infection practitioners, have contributed substan-
tially to reducing the morbidity and mortality of the disease.
A detailed analysis of these trials is not relevant here, but, as
an example of a non-antibiotic strategy that recently
attracted much attention, I will brieﬂy discuss the concept of
early goal-directed therapy.
During the 1980s, several investigators, notably William
Shoemaker, suggested that clinical outcomes in sepsis might
be improved by manipulating haemodynamic variables to
some predeﬁned targets that would optimize oxygen delivery
and utilization by the tissues. Attaining a cardiac index
>4.5 L/min/m2, an oxygen delivery index >600 mL/min/m2,
and oxygen consumption >170 mL/min/m2 became the
‘goals’, and the strategy was ‘goal-directed therapy’. Unfortu-
nately, the subsequent clinical trial evidence did not show
that this ‘one size ﬁts all’ approach was effective, and it fell
into disuse. It was against this background that, in 2001, Riv-
ers published a startling paper in which he described the
effects of early goal-directed therapy, a more customized
approach used for the ﬁrst 6 h after patients presented in
the emergency room with sepsis [9]. In a prospective, ran-
domized controlled trial of 263 patients, the in-hospital mor-
tality was 30.5% in the treatment group vs. 46.5% in the
controls, a remarkable 16% drop in relative mortality and a
highly signiﬁcant result (p 0.009). This was achieved with a
relatively straightforward protocol, in which central venous
pressure, mean arterial pressure and central venous oxygen
saturation (ScvO2) were monitored and manipulated with
ﬂuids or vasoactive drugs to achieve predeﬁned endpoints.
Subsequently, the generalizability of this approach has
been challenged, and a further clinical trial is currently under-
way to determine whether the ﬁndings can be conﬁrmed.
Nevertheless, it is a good illustration of how detailed atten-
tion to ﬂuid management, vasopressor use and optimization
of oxygen delivery are critical to the ‘non-antibiotic’ manage-
ment of sepsis. A comprehensive consensus statement that
summarizes the evidence for various aspects of supportive
care has recently been published [10].
Bacterial Targets
It would seem axiomatic that bacterial virulence factors
should be highly attractive therapeutic targets, as presumably
they initiate the pathological effects of the infection, even if
in sepsis it is host mechanisms that perpetuate and amplify
those effects.
An important concept to emerge in recent years has been
that of pathogen-associated molecular patterns (PAMPs) and
their role in engaging the host innate immune response in
what I have termed the molecular architecture of sepsis [11]
(Fig. 1). At its core, the host–pathogen interaction needs a
mechanism by which the elements of the host innate
immune system can recognize, and respond to, the presence
of bacteria. PAMPs constitute one side of this interaction;
pathogen recognition receptors (see below) constitute the
other.
Many PAMPs have been identiﬁed and their structure has
been described in great detail (some examples are shown in
Table 2); several of them have been intensively investigated
as potential therapeutic targets. Two examples will serve to
demonstrate both the principles and the frustrations of this
approach.
Gram-negative endotoxin
A very substantial body of evidence has implicated endotoxin
(lipopolysaccharide (LPS)) of Gram-negative bacteria as a
major cause of the myriad of physiological changes seen in
the septic patient (reviewed in [12,13]), and LPS was proba-
bly the very ﬁrst target for the development of a non-antibi-
otic treatment for sepsis. Injecting animals with LPS can
TABLE 1. General approaches to the adjunctive treatment
of sepsis
Strategy Example
Improve supportive care Oxygenation/ventilation strategies;
optimize ﬂuid/vasopressor use; early
goal-directed therapy
Target bacterial virulence factors Anti-endotoxin antibodies,
endotoxin-removal columns
Target host response factors Corticosteroids; anticytokine drugs;
anticoagulants
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reproduce most of the pathological features of sepsis, and
experimental approaches that remove or neutralize LPS can
successfully modify the disease; animals that are genetically
resistant to LPS are essentially protected from the lethal
effects of LPS. Furthermore, LPS can be found in the circula-
tion of many (but not all) patients with septic shock, includ-
ing, interestingly, some with Gram-positive infections. Yet in
the main, the clinical development of anti-endotoxin strate-
gies has been unsuccessful. The single (possible) exception is
a Japanese product that acts as an extracorporeal LPS-
removal device; this is commercially available in Japan, but
controlled trial data from Europe have not provided clear
evidence of beneﬁt [14]. There are a number of possible rea-
sons for this failure, including the probably transitory nature
of endotoxin in the circulation, and problems in generating
an effective neutralizing antibody to the lipid-containing ‘toxic
core’ of LPS.
Exotoxins from Gram-positive bacteria
The second example of PAMPs comes from Gram-positive
bacteria. Exotoxins from staphylococci and streptococci
should theoretically be much easier targets. Exotoxins such
as toxic shock syndrome-1 from S. aureus and the pyrogenic
exotoxins of Streptococcus pyogenes are proteins (and there-
fore much more amenable to antibody neutralization), and
are clearly implicated in the pathogenesis of conditions such
as staphylococcal or streptococcal toxic shock syndromes
(reviewed in [15,16]). Here again, though, the clinical devel-
opment of therapeutic agents has been frustrated, in this
case because there are no good assays with which to dem-
onstrate the presence of the toxins in the circulation, and
because these conditions are relatively uncommon; by the
time they have been clinically identiﬁed, it is probably too
late to be able to intervene usefully with antitoxin drugs or
antibodies.
Targeting bacterial PAMPs remains a theoretically very
attractive approach, and will continue to attract considerable
interest, but for the moment there are signiﬁcant practical
problems to be overcome.
Host Targets
As we have seen, although bacteria (through their PAMPs)
initiate the septic response, it is the dysregulated host
immune response that ampliﬁes the process and causes the
cellular injury that ultimately leads to the characteristic
picture of multiorgan failure. There have been phenomenal
advances in understanding the intricacies of the host
response to sepsis which have been well reviewed elsewhere
[17], and these have provided a rich source of potential tar-
gets [18] (Table 3). Broadly, two different approaches have
been pursued: what might be called ‘immunosuppression’,
FIG. 1. Sepsis is driven by components of
both the host and the bacterial pathogen. The
molecular basis of both the microbial virulence
factors and the host immune response have
been extensively investigated and character-
ized. IR, immune response.
TABLE 2. Examples of bacterial virulence determinants
(pathogen-associated molecular patterns) associated with
initiation of the septic response
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aimed at several points in the inﬂammatory pathway, and
‘immunotherapy’, in which drugs are aimed at speciﬁc key
elements.
Immunosuppression—steroids and intravenous
immunoglobulin (IVIG) as examples
The ﬁrst major clinical trials of steroids in the treatment of
sepsis date back to the 1980s. A substantial body of preclini-
cal data had suggested that many of the manifestations of
sepsis were due to excess inﬂammation, and that anti-inﬂam-
matory doses of steroids would be beneﬁcial. Indeed, in
various animal models, including primates, steroids were very
effective. On the basis of these ﬁndings, two large clinical
trials of high-dose steroids were conducted and both
concluded that these high-dose regimens were not effective
in preventing death from sepsis, or, indeed, were perhaps
even harmful, increasing the risk of superinfection [19,20].
More recently, Annane et al. suggested that some septic
patients failed to respond adequately to the physiological
‘stress’ that occurs in sepsis. On the basis of pilot data
showing that small doses of hydrocortisone reduced vaso-
pressor dependency, they proceeded to carry out a prospec-
tive, randomized controlled trial in which patients with
septic shock received replacement doses of hydrocortisone
plus ﬂudrocortisone or matching placebos, for 7 days [21].
They enrolled 300 patients, and the main outcome measure
was 28-day survival in patients who were shown to have
adrenocortical insufﬁciency on the basis of a corticotropin
test. There were fewer deaths in the active treatment group:
73 vs. 60, p 0.02.
It is still not clear whether this approach is genuinely
based on ‘replacement therapy’ or is, in fact, simply a more
modest dose of immunosuppression, and, indeed, the recent
CORTICUS trial, which attempted to repeat the ﬁndings of
the original study, failed to reproduce the beneﬁcial outcome
[22]. A recently updated meta-analysis has tentatively con-
cluded that low-dose steroids are beneﬁcial for the subset of
patients at high risk of death [23] but, in the absence of a
trial that speciﬁcally addresses this question, the debate is
likely to continue for some time.
The use of IVIG in sepsis also has a long history [24]. It
was initially thought that it might be useful because it con-
tained anti-endotoxin antibodies [25] but, despite several
clinical trials, this idea never really gained currency, and IVIG
has largely disappeared from routine clinical use for sepsis
with the exception of patients with streptococcal toxic
shock syndrome (STSS). Group A streptococci produce exo-
toxins that have the property of superantigens, and it is this
that is thought to underlie many of the manifestations of
STSS (reviewed in [15]). Commercial preparations of IVIG
contain antibodies to one of the major streptococcal exo-
toxins, streptococcal pyrogenic exotoxin A, [26], and it was
thought that this might explain the somewhat anecdotal clini-
cal evidence that large doses of IVIG seemed to be beneﬁcial
in this disease [27,28]. However, it has subsequently
emerged that streptococcal pyrogenic exotoxin A is just one
of many superantigenic toxins produced by streptococci, and
it is not even the most potent.
If IVIG is indeed effective—and the clinical trial data are
not of level 1 quality, either for STSS or, more generally, for
sepsis [29]—then it is more likely that it is acting as a
non-speciﬁc immunosuppressant, in much the same way as it
is effective in idiopathic thrombocytopenic purpura. In a very
real sense, treating severe infection with immunosuppres-
sives is counterintuitive, and the risk of making things worse
and/or causing secondary infections is one of the main
concerns with this approach. A more attractive strategy is
targeted immunotherapy.
Immunomodulation—targeting speciﬁc pathways
Cytokines. Tumour necrosis factor (TNF) is probably the best
known example of a speciﬁc cytokine mediator that has been
extensively investigated as a therapeutic target for sepsis
(reviewed in [30]). Various strategies were pursued, including
both polyclonal and monoclonal antibodies, antibody frag-
ments, and receptor constructs. However, despite a substan-
tial body of encouraging preclinical evidence and several
large phase III clinical trials, no anti-TNF strategy has suc-
ceeded. Subsequently, other anticytokines were also investi-
gated, including interleukin-1 receptor antagonist and
interleukin-6 antibody, with similar outcomes. The reasons
for these failures have been much debated [31]. A commonly
held view is that redundancy of the cytokine network means
that neutralizing or blocking a single pathway will fail to
interrupt the overall process; thus, even if we successfully
neutralize TNF, for instance, the inﬂammatory process will
simply ‘bypass’ the blockade and continue unabated. This
may be partly true, although it does not explain why blocking
TABLE 3. Some examples of components of the host immune










A7 nicotinic acetylcholine receptors
For a full discussion, see [18].
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cytokines in animal models is so successful. It is certainly
true that both TNF and interleukin-1 are ‘early-response’
cytokines, and that attempts to block them in clinical prac-
tice may simply be too late. However, another view is that
the studies failed not because the underlying science was
‘wrong’, but because of the challenges in carrying out clinical
trials in a very complex patient population [32]. What is cer-
tainly true is that most of the clinical trials of the anticytoki-
ne reagents were hampered by the fact that there was no
good way of showing that patients actually had a derange-
ment of the target molecule (e.g. a raised TNF serum level)
at the time that the drug (e.g. anti-TNF) was administered.
This meant that many patients were entered into the trials
who were probably unlikely to beneﬁt, increasing the ‘signal-
to-noise’ ratio and making it harder to achieve a statistically
signiﬁcant result.
Coagulation cascade. It had been known for some time that
the coagulation cascade was just one of several pathways
that were deranged in septic patients. Drotrecogin alfa (acti-
vated) (activated protein C) was developed on the basis of
the observation that protein C, a naturally occurring antico-
agulant protein, was consumed in sepsis and that the extent
of the consumption correlated with the outcome. Preclinical
studies showed that replacement with activated protein C
prevented death in animal models of sepsis. The landmark
study by Bernard et al. [33] showing a survival beneﬁt with
drotrecogin alfa (activated), led to registration by both the
European Medicines Agency and the US Food and Drug
Administration, and approval from the National Institute for
Health and Clinical Excellence for its use in deﬁned clinical
settings. Nevertheless, the lack of a second conﬁrmatory
clinical trial and the failure of the ADDRESS study in lower-
risk patients [34] means that many intensive-care specialists
remain uncertain about the precise role of this drug. Indeed,
a very recent Cochrane review concluded that ‘‘Unless addi-
tional RCTs provide evidence of a treatment effect, policy-
makers, clinicians and academics should not promote the use
of (activated protein C)’’ [35]. Notwithstanding the ongoing
debate about the efﬁcacy of the drug [36] (and its mode of
action), drotrecogin alfa (activated) provides an interesting
example of the next level of sophistication of the drug devel-
opment programme, because protein C can be measured in
septic patients, and, indeed, a trial currently in progress is
measuring serum levels in real time and modifying therapy
accordingly.
Toll-like receptors. I noted above that the host–pathogen
interaction has two components: the ﬁrst comprises bacterial
PAMPs; these are then recognized by the second element,
pathogen recognition receptors on host cells. Toll-like recep-
tors (TLRs) are a family of receptors that sense PAMPs and
initiate a signal that is handed through a cascade of mole-
cules, leading to activation of nuclear factor-jB and, ulti-
mately, mRNA transcription of cytokines (for reviews see
[37–39]). TLR4 turned out to be the long-sought receptor
for endotoxin, and quickly became a potential drug target
[40,41]. Preclinical studies have already been completed, and
clinical trials are underway. It remains to be seen whether
blocking endotoxin sensing at the level of TLR4 will be effec-
tive. One concern is that by the time the clinical manifesta-
tions of endotoxaemia are apparent, blocking the receptor
may be too late—locking the stable door after the horse has
bolted.
Conclusions
Reducing the mortality due to sepsis and septic shock is a
key medical need that remains unmet, but designing the
appropriate vehicle with which to evaluate new agents has
been particularly challenging. More than 10 years ago, inves-
tigators began to think about some of the practical difﬁcul-
ties (see, for instance, a series of reviews in [42]), and
many of the concerns about sample size, use of appropriate
deﬁnitions, and statistical methodology have been revisited
more recently [43,44]. Such has been the concern that we
have suggested that a better approach would be to aban-
don the attempt to design trials in ‘sepsis’ as such, but
instead to focus on speciﬁc infectious disease syndromes
associated with markers of severity [32]. It is salutary to
note that, more than 10 years after we reviewed the ﬁeld
of adjunctive therapy for sepsis [45], there is still only one
licensed drug available despite several thousand patients
having been entered in large international clinical trials. The
articles included in this current special theme section of
the journal describe the ongoing efforts to establish new
treatment modalities for what remains a highly challenging
disease.
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